Association between regular thyroxin use and thyroid cancer

Association between regular thyroxin use and thyroid cancer Reactions 1664, p8 - 12 Aug 2017 Association between regular thyroxin use and thyroid cancer There seems to be an association between the regular use of thyroxin in patients with primary hypothyroidism and the development of thyroid cancer, according to study results reported in the Journal of Clinical Pharmacology, although "additional studies are needed to further evaluate and validate these finding". The study retrieved data from the Longitudinal Health Insurance Database 2005 (LHID2005) in Taiwan. The 1285 patients diagnosed with new-onset thyroid cancer in 2001–2013 were matched with 3855 controls without thyroid cancer. A prior hypothyroidism diagnosis was present in 37 cases (2.88%) and 33 controls (0.86%). In conditional regression analysis, cases were more likely to have hypothyroidism than controls (adjusted odds ratio [OR] 3.01; 95% CI 1.85, 4.89; p<0.001). In patients with hypothyroidism, there was a significant association with thyroid cancer in those who had received continuous thyroxin prescriptions for ≥60 days within 6 months of cancer diagnosis (OR 8.68; 4.34, 17.34; p<0.001) but not in those who were irregular thyroxin users (OR 0.32; 0.09, 1.10). "Although the true role of thyroxin in thyroid cancer development remains to be investigated," note the authors, "physicians might consider this association when treating patients with subclinical hypothyroidism". Hung S-H, et al. Thyroxin Use Is Associated With Increased Risk of Thyroid Cancer in Patients With Hypothyroidism. Journal of Clinical Pharmacology : 19 Jul 2017. Available from: URL: 803263076 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 Reactions Weekly Springer Journals

Association between regular thyroxin use and thyroid cancer

Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial